David A. Siegel Immunocore Holdings PLC Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 523,400 shares of IMCR stock, worth $18.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

523,400

Previous 604,900 13.47%

Holding current value

$18.9 Million

Previous $17.8 Million 12.97%

% of portfolio

0.04%

Previous 0.04%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$28.21 - $33.0 $2.3 Million - $2.69 Million	-81,500 Reduced 13.47%	523,400 $15.5 Million
Q4 2024 Feb 14, 2025	SELL	$28.14 - $34.69 $4.3 Million - $5.3 Million	-152,800 Reduced 20.17%	604,900 $17.8 Million
Q3 2024 Nov 14, 2024	BUY	$30.06 - $41.49 $9.02 Million - $12.5 Million	300,200 Added 65.62%	757,700 $23.6 Million
Q2 2024 Aug 14, 2024	BUY	$33.78 - $63.75 $12.5 Million - $23.6 Million	370,900 Added 428.29%	457,500 $15.5 Million
Q1 2024 May 15, 2024	SELL	$60.14 - $75.36 $48,112 - $60,288	-800 Reduced 0.92%	86,600 $5.63 Million
Q4 2023 Feb 14, 2024	SELL	$42.85 - $69.5 $946,985 - $1.54 Million	-22,100 Reduced 20.18%	87,400 $5.97 Million
Q3 2023 Nov 14, 2023	SELL	$49.5 - $66.6 $4,950 - $6,659	-100 Reduced 0.09%	109,500 $5.68 Million
Q2 2023 Aug 14, 2023	BUY	$48.54 - $61.64 $4.4 Million - $5.59 Million	90,700 Added 479.89%	109,600 $6.57 Million
Q1 2023 May 15, 2023	BUY	$46.12 - $65.71 $871,668 - $1.24 Million	18,900 New	18,900 $934,000

Others Institutions Holding IMCR

# of Institutions

128

Shares Held

44.6M

Call Options Held

219K

Put Options Held

125K

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.58B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account